• Saltar a la navegación principal
  • Saltar al contenido principal
  • Saltar al pie de página
ILAPHAR | Revista de la OFIL

ILAPHAR | Revista de la OFIL

Revista de la Organización de Farmacéuticos | Ibero-latinoamericanos | Ibero Latin American Journal of Health System Pharmacy

  • Números de la revista
  • Sobre la Revista
  • Eventos y Publicaciones

Intravenous antineoplastic drugs that can interfere with driving and categorization according to the DRUID Project

Fecha de recepción: 09/03/2018  –  Fecha de aceptación: 15/05/2018

García Muñoz S, García Martínez T, Soler Company E, Medina Guerrero A, Seguí Gregori I, Montesinos Ortí S

Servicio de Farmacia. Hospital Arnau de Vilanova-Lliria. Valencia (España)

____

Correspondencia:

Sergio García Muñoz

Hospital Arnau de Vilanova-Lliria

Edificio Consultas Externas

(Servicio de Farmacia)

C/ San Clemente, 12

46015 Valencia

Correo electrónico: garcia_sermun@gva.es

____

SUMMARY

Objectives: To identify the intravenous antineoplastic active principles with some effect on the driving of vehicles, to categorise them according to the methodology proposed in the project «DRiving Under the Influence of Drugs, Alcohol and Medicines» (DRUID) and to implement an information system for patients and professionals.

Material and methods: Those intravenous antineoplastic active principles prepared in the pharmacy service during the year 2017 in which the driving pictogram appeared on the cardboard or on the website of the Spanish Medicines Information Centre of the Spanish Agency for Medicinal Products and Medical Devices were included. For the categorization of drugs according to their influence on driving capacity, the methodology proposed in the DRUID project was followed.

Results: 67 different medications were reviewed, of which 49 (73.13%) included the driving pictogram. The resulting distribution between categories was 27 Category I (55.10%) and 22 Category II (44.90%) drugs. Adverse reactions to these medications that may affect driving were neurological disorders in 34 medications, psychiatric disorders in 14, eye disorders in 13, and hearing disorders in 9. An adapted driving pictogram was added to the patient information sheets and an information poster for patients and healthcare professionals was designed.

Conclusions: Patients with cancer undergoing treatment with oncohaematological drugs may have their driving ability affected to different degrees depending on the type and severity of adverse effects. For this reason, the categorisation of medicines according to the DRUID classification is very useful.

Key Words: Accidents traffic, automobile driving, antineoplastic agents, adverse drug reaction, traffic, DRUID proyect, cancer.

____

Download PDF: Medicamentos antineoplásicos intravenosos que pueden interferir en la conducción y su categorización según el proyecto DRUID

Footer

Footer 1

ISSN Edición impresa: 1131-9429
ISSN Edición electrónica: 1699-714X

Web diseñada y desarrollada por Company Valor